TRS 007
Alternative Names: PD-1 nano-mAb; TRS-007Latest Information Update: 03 Mar 2022
At a glance
- Originator Zhejiang Teruisi Pharmaceutical
- Class Antineoplastics; Immunotherapies; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Cancer
Most Recent Events
- 02 Mar 2022 Investigation of TRS 007 in Cancer is ongoing in China (Parenteral) (Zhejiang Teruisi Pharmaceutical, March 2022)